Lung Cancer | Specialty

Building on Momentum Is Vital in Lung Cancer

February 8th 2020

Advancements in the prevention and treatment of patients with lung cancer have picked up momentum over the past decade and now is the time to build on that progress according to Suresh S. Ramalingam, MD, FASCO.

Emerging Targeted Therapies Emphasize Need for Molecular Testing in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.

Perseverance Is the Name of the Game With HER3 Research in Solid Tumors

February 5th 2020

Despite a reasonable expectation that expression of HER3 and its ligand heregulin would be predictive biomarkers for HER3-targeted therapy, their usefulness in clinical trials has been hit-and-miss. Nevertheless, investigators have persevered, and new types of drugs have largely supplanted the first generation in clinical trials.

Immunotherapy Research Continues to Improve Patient Selection in NSCLC

February 5th 2020

Roy S. Herbst, MD, PhD, discusses research regarding immunotherapy and accompanying biomarkers in non–small cell lung cancer.

Brigatinib Regulatory Status in NSCLC

February 4th 2020

ALTA-1L Trial: Do Results Affect ALK TKI Sequencing?

February 4th 2020

Managing ALK-Positive NSCLC Disease Progression

February 4th 2020

ALTA-1L Regimen: Patient Selection Versus Other ALK TKIs

February 4th 2020

The ALTA-1L Phase III Trial

February 4th 2020

Immuno- and Chemotherapy Approach to R/R NSCLC

February 4th 2020

A Retrospective Look at ALK-Rearranged NSCLC Management

February 4th 2020

Investigators Seek New Standard in RET Fusion–Positive NSCLC

February 4th 2020

Investigators hope selpercatinib (LOXO-292), a highly selective RET inhibitor, will demonstrate potential as a new standard of care for patients with advanced or metastatic treatment-naïve RET fusion–positive non–small cell lung cancer in the phase III LIBRETTO-431 (NCT04194944) trial.

Dinutuximab Misses Survival Endpoint in Small Cell Lung Cancer

February 3rd 2020

The addition of dinutuximab injection to irinotecan did not improve overall survival compared with irinotecan or topotecan alone in patients with relapsed/refractory small cell lung cancer, missing the primary endpoint of the phase II/III DISTINCT trial.

EU Application Withdrawn for Frontline Nivolumab/Ipilimumab in NSCLC

February 3rd 2020

Bristol-Myers Squibb has withdrawn its application in the European Union for the frontline combination of nivolumab and ipilimumab as a treatment for patients with advanced non–small cell lung cancer.

Immunotherapy Opens Doors in Small Cell Lung Cancer

February 2nd 2020

Immune checkpoint inhibitors have yielded modest improvement in small cell lung cancer (SCLC), but have already reshaped the management of this tumor type and helped open the door to the exploration of other, potentially more effective treatment approaches, according to a panel of thoracic oncology experts who discussed the treatment horizon for SCLC in a recent OncLive Peer Exchange® panel.

Dr. Saxena on the Future of Next-Generation ALK Inhibitors in NSCLC

January 31st 2020

Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.

Dr. Saxena on Available Next-Generation ALK Inhibitors in NSCLC

January 31st 2020

Ashish Saxena, MD, PhD, discusses available next-generation ALK inhibitors in non–small cell lung cancer.

Dr. Rotow on Remaining Questions With Brigatinib in ALK+ NSCLC

January 31st 2020

Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non­–small cell lung cancer.

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

January 31st 2020

Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.

Dr. Rotow on First-Line Brigatinib Versus Crizotinib in ALK+ NSCLC

January 31st 2020

Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non